UMBELLATINE

Metformin

Tianjin Anding HospitalSmall moleculePhase 4 / ApprovedActive

BB

65/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 50/ 100
Competitive Position: 95/ 100

Competitive context

5 Active assets in the Metformin cohort.

Asset / Sponsor	Phase	Rating
Letrozole Shanghai 10th People's Hospital	Phase 4	BBB
Metformin RenJi Hospital	Phase 4	BBB
Chiglitazar Shengjing Hospital	Phase 2/3	B
INSULIN SUSP ISOPHANE RECOMBINANT HUMAN University Hospital, Strasbourg, France	Phase 2	CCC
Semaglutide RenJi Hospital	N/A	D
Liraglutide RenJi Hospital	N/A	D

Same molecule, other indications

UMBELLATINE is also rated in:

inherited lipid metabolism disorderDormant

BBB

Indicative ·

72 / 100

abdominal obesity-metabolic syndromeDormant

BB

Indicative ·

69 / 100

metabolic dysfunction-associated steatotic liver diseaseDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.